This content is machine translated Multiple sclerosis Personalized medicine at the cutting edge Intensive research in the field of multiple sclerosis (MS) has led to the availability of different treatment options – depending on the form of the disease and its severity. This…
View Post 6 min This content is machine translated Chronic myeloid leukemia State of the Art – where are we at CML in 2017? CML patients have a normal life expectancy when treated with Abl-specific kinase inhibitors (TKIs) in chronic phase. Imatinib, dasatinib and nilotinib are approved in the first-line treatment of CML. In…
